Old Web
English
Sign In
Acemap
>
authorDetail
>
Amie Patel
Amie Patel
Cornell University
Medicine
Prostate cancer
castration resistant
dose escalation
Oncology
4
Papers
0
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A phase I/II dose-escalation study of fractionated and multiple dose 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC).
2021
Journal of Clinical Oncology
Michael Sun
Jones T. Nauseef
Justin M Lebenthal
Muhammad Junaid Niaz
Sharon Singh
Tessa A Chamberlain
Mahelia Bissassar
Amie Patel
Angela Tan
Shankar Vallabhajosula
John W. Babich
Paul J. Christos
Joseph R. Osborne
Ana M. Molina
Cora N. Sternberg
David M. Nanus
Neil H. Bander
Scott T. Tagawa
Show All
Source
Cite
Save
Citations (0)
Baseline and post-treatment circulating tumor cell (CTC) counts with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) in men with metastatic castration-resistant prostate cancer (mCRPC).
2021
Journal of Clinical Oncology
Michael Sun
Justin M Lebenthal
Jones T. Nauseef
Muhammad Junaid Niaz
Sabrina Guervil
Escarleth Fernandez
Amie Patel
Angela Tan
Panagiotis J. Vlachostergios
Joseph R. Osborne
Ana M. Molina
Cora N. Sternberg
David M. Nanus
Neil H. Bander
Scott T. Tagawa
Show All
Source
Cite
Save
Citations (0)
Open label phase II trial of cabozantinib (cabo) in patients with metastatic castrate resistant prostate cancer (mCRPC) and known amplifications or activating mutations in gene targets who have received prior anti-androgen therapy.
2021
Journal of Clinical Oncology
Jones T. Nauseef
Sharon Singh
Angela Tan
Amie Patel
Brian D. Robinson
Francesca Khani
Charles G. Drake
Emerson A. Lim
Mark N. Stein
Elisabeth I. Heath
Himisha Beltran
Ana M. Molina
Bishoy Faltas
Karla V. Ballman
Cora N. Sternberg
Scott T. Tagawa
David M. Nanus
Show All
Source
Cite
Save
Citations (0)
Patient-reported outcomes (PRO) from a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer (mCRPC).
2020
Journal of Clinical Oncology
Panagiotis J. Vlachostergios
Sukanya Goswami
Muhammad Junaid Niaz
Charlene Thomas
Paul J. Christos
Joseph R. Osborne
Shankar Vallabhajosula
Ana M. Molina
Cora N. Sternberg
Sharon Singh
Angela Tan
Amie Patel
David M. Nanus
Neil H. Bander
Scott T. Tagawa
Show All
Source
Cite
Save
Citations (0)
1